ClinicalTrials.gg
RecruitingNCT06809400Updated Oct 14, 2026

A Study of LY4006896 in Healthy Participants and Participants With Parkinson's Disease

A Phase 1 interventional study of LY4006896 and Placebo in Parkinson Disease, sponsored by Eli Lilly and Company. Recruiting at 14 sites in 2 countries. Open to participants aged 30 Years to 85 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-14.

Sponsored by Eli Lilly and Company · Phase 1, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Feb 2025; still recruiting 1 year 9 months later.
Updated Oct 14, 2026Primary completion movedStudy completion moved+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
90
Allocation
Randomized
Ages
30 Years to 85 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 11 studies in Parkinson Disease by Eli Lilly and Company — 2 open to participants now, 3 under way, none of them phase 3. Parkinson Disease · Eli Lilly and Company.

Planned enrollment
5th of 10
90 · median 85
Started
2025
the only one that year
Phase 1
3 of 11
2 open now
Registered
11th of 11
by date

Among the 11 studies in Parkinson Disease by Eli Lilly and Company, this one is the 5th largest by planned enrollment of the 10 interventional ones that give a count, is the only one that started in 2025, is one of 3 in phase 1, and was the 11th registered.

Parkinson Disease

4,581 studies on the registry are indexed under Parkinson Disease; 1,086 are open to participants now.

Browse Parkinson Disease studies →

Open to participants now

2 of the 11 studies in Parkinson Disease by Eli Lilly and Company are open now, in 5 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Who these studies take

Of the 752 Parkinson Disease studies recruiting now, 313 (42%) set no upper age limit and 127 (17%) stop at 75 or younger; 64 take children under 18; 189 take healthy volunteers.

This study: 30 Years to 85 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 11 studies in Parkinson Disease by Eli Lilly and Company, or all of them as a file.
02

Study summary

The purpose of this study is to generate evidence of the safety, tolerability, and pharmacokinetics/pharmacodynamics of IV LY4006896 compared with placebo in healthy participants and participants with Parkinson's disease.

Read the detailed description

The screening period will be up to 120 days for participants with Parkinson's disease who receive up to 4 doses, and up to 35 days for healthy participants who receive 1 dose. The treatment and follow-up duration will be up to 61 weeks for participants with Parkinson's disease, and 48 weeks for healthy participants.

The total study duration will be up to 78 weeks for participants with Parkinson's disease, and 53 weeks for healthy participants.

03

Conditions studied

  • Parkinson Disease

Browse trials for

04

Who can participate

The criteria were revised on the registry on Oct 14, 2026. See what changed

Ages eligible
30 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Part A Single Ascending Dose (SAD) and B Multiple Dose (MD)

  • Have a within the range of 18 to 34 kilogram per square meter (kg/m²) (inclusive).
  • For Japanese participants: To qualify as a participant of first-generation Japanese origin, the participant, the participant's biological parents, and all of the participant's biological grandparents must be of exclusive Japanese descent and born in Japan.
  • Have venous access sufficient to allow for blood sampling or administration of study intervention for IV administration, or both.

Part A (SAD) Only

  • Participant must be 30 to 85 years of age (inclusive), at the time of signing the
  • Are overtly healthy
  • For Chinese participants: To qualify as Chinese for this study, all 4 of the participant's biological grandparents must be exclusive Chinese descent and born in China.

Part B (MD) Only

  • Participant must be 40 to 85 years of age (inclusive), at the time of signing the informed consent
  • Diagnosis of Parkinson's disease per United Kingdom (UK) Parkinson's Disease Society Brain Bank Clinical Diagnostic Criteria.
  • If presently untreated for Parkinson's disease, clinical status is not expected to require changes in symptomatic treatment within 52 weeks from baseline.
  • If presently being treated for Parkinson's disease, receiving a stable dose of symptomatic dopaminergic therapy, including monoamine oxidase-B inhibitor, levodopa/carbidopa or dopamine agonist for at least 90 days prior to baseline and not expected to change within 52 weeks.
  • Have a (MoCA) score of greater than or equal to (≥) 24.

Exclusion criteria

Exclusion Criteria:

Part A (SAD) and B (MD)

  • Have significant neurological disease affecting the central nervous system (CNS) (other than Parkinson's disease in Part B cohorts) that may affect the participant's ability to complete the study.
  • Have a history or presence of serious or unstable illnesses or conditions that, in the investigator's opinion, could interfere with the analyses in this study, or increase risk for study intervention administration, or result in a participant's of less than 24 months.
  • Have known allergies to LY4006896, related compounds, or any components of the formulation, or history of allergic reactions to any transferrin receptor antibodies.
  • Have significant allergies to humanize monoclonal antibodies.
  • Have multiple or severe drug allergies (including, but not limited to, erythema multiforme major, linear immunoglobulin A dermatosis, toxic epidermal necrolysis, or exfoliative dermatitis); or intolerance to topical , or severe posttreatment reactions.
  • Have history or presence of uncontrolled asthma, significant disease, hereditary angioedema, or known history of common variable immune deficiency.
  • Evidence of clinically significant anemia.

Part A (SAD) Only

  • Have an abnormal blood pressure or pulse rate, or both, as determined by the investigator, or a preexisting history of hypertension.

Part B (MD) Only

  • Have an abnormal blood pressure or pulse rate, or both, as determined by the investigator, or have uncontrolled hypertension, defined as a systolic blood pressure greater than (>) 150 mmHg or a diastolic blood pressure >95 mmHg at Screening or Treatment Visits.
  • Have an implanted deep brain stimulation (DBS) system or any other implanted neurostimulation device (including but not limited to spinal cord stimulation, vagus nerve stimulation or neuromodulation devices)
  • Are receiving continuous infusion therapy with anti-parkinsonian medications, including but not limited to subcutaneous foslevodopa-foscarbidopa, subcutaneous apomorphine, or intraduodenal/intestinal levodopa formulations

Diagnostic assessments

  • 6.5 percent (%) or higher
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

MMSE and MoCA

Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
90 participants (estimated)

Study arms

  • Experimental
    Part A LY4006896 + Placebo

    Healthy participants will receive a single escalating dose of LY4006896 and matching placebo.

    Drug: LY4006896

  • Experimental
    Part B LY4006896 + Placebo

    Participants with Parkinson's disease will receive multiple doses of LY4006896 and matching placebo.

    Drug: Placebo

Interventions

  • DrugLY4006896

    Administered intravenously (IV)

  • DrugPlacebo

    Administered IV

06

What researchers measure

Primary outcomes

  1. Number of Participants with One or More Serious Adverse Event(s) (SAEs) Part A

    Time frame: Baseline to Week 48

  2. Number of Participants with One or More Treatment-Emergent Adverse Events (TEAEs) Part A

    Time frame: Baseline to Week 48

  3. Number of Participants with One or More SAEs Part B

    Time frame: Baseline to Week 61

  4. Number of Participants with One or More TEAEs Part B

    Time frame: Baseline to Week 61

Secondary outcomes

  1. Pharmacokinetics (PK): Maximum Concentration (Cmax) of LY4006896 ARC-Associated Antisense Part A

    Time frame: Baseline to Week 48

  2. PK: Cmax of LY4006896 ARC-Associated Antisense Part B

    Time frame: Baseline to Week 61

  3. PK: Area Under the Concentration versus Time Curve (AUC) of LY4006896 ARC-Associated Antisense Part A

    Time frame: Baseline to Week 48

  4. PK: AUC of LY4006896 ARC-Associated Antisense Part B

    Time frame: Baseline to Week 61

  5. Effect of LY4006896 on Aggregation-Competent Alpha-Synuclein in Skin Part B

    Alpha-synuclein seed amplification positivity

    Time frame: Baseline to Week 61

  6. Effect of LY4006896 on Aggregation-Competent Alpha-Synuclein in Cerebrospinal Fluid (CSF) Part B

    Alpha-synuclein seed amplification positivity

    Time frame: Baseline to Week 61

07

Study locations

11 of 14 sites recruiting
  • Collaborative Neuroscience Network - CNS
    Los Alamitos, California 90720, United States
    Recruiting
    • · Contact844-424-9494
    • Steven Reynolds · Principal investigator
  • Collaborative Neuroscience Network - CNS
    Los Alamitos, California 90720, United States
    Recruiting
    • · Contact562-742-7116
    • Omid Omidvar · Principal investigator
  • K2 Medical Research, LLC
    Maitland, Florida 32751, United States
    Completed

    Not enrolling at this site.

  • Aqualane Clinical Research
    Naples, Florida 34105, United States
    Recruiting
    • · Contact239-529-6780
    • William Justiz · Principal investigator
  • Charter Research
    Orlando, Florida 32803, United States
    Recruiting
    • · Contact407-337-1000
    • Diana Balsalobre · Principal investigator
  • Progressive Medical Research
    Port Orange, Florida 32127, United States
    Recruiting
    • · Contact386-304-7070
    • Alexander White · Principal investigator
  • K2 Medical Research, LLC
    The Villages, Florida 32159, United States
    Recruiting
    • · Contact321-278-5590
    • Craig Curtis · Principal investigator
  • Charter Research
    The Villages, Florida 32162-2698, United States
    Recruiting
    • · Contact352-775-1000
    • Jeffrey Norton · Principal investigator
  • QUEST Research Institute
    Farmington Hills, Michigan 48334, United States
    Recruiting
    • · Contact248-957-8940
    • Aaron Ellenbogen · Principal investigator
  • PPD Development, LP
    Austin, Texas 78744, United States
    Recruiting
    • · Contact877-773-3707
    • Sabrina Merchant · Principal investigator
  • Evergreen Health Research
    Kirkland, Washington 98034, United States
    Not yet recruiting
    • · Contact425-899-5385
    • Pinky Agarwal · Principal investigator
  • Inland Northwest Research
    Spokane, Washington 99202, United States
    Not yet recruiting
    • · Contact509-960-2818
    • Jason Aldred · Principal investigator
  • P-One Clinic
    Hachiōji, 192-0071, Japan
    Recruiting
    • · Contact81120023812
    • Kenichi Furihata · Principal investigator
  • Oita University Hospital
    Yufu, 879-5593, Japan
    Recruiting
    • · Contact81120023812
    • Naoto Uemura · Principal investigator
08

References and documents

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2025 (actual). Primary completion is estimated for Oct 2028, 44 months after the start.

Of 127 industry-sponsored phase 1 interventional studies under Parkinson Disease, half reached primary completion within 9 months of starting (the median), counting those still running; a quarter within 3 and three quarters within 24. This study's planned 44 months is above that.

Counting every sponsor, half of 204 studies reached it within 18 months; a quarter within 5 and three quarters within 40.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 14, 2026: primary completion Jan 2028 → Oct 2028 and completion Jan 2028 → Oct 2028.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jan 31, 2025
First posted
Feb 5, 2025
StartActual
Feb 18, 2025
Primary completionEst.
Oct 2028was Jan 2028
CompletionEst.
Oct 2028was Jan 2028
Last update
Oct 14, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Jan 2028→Oct 2028
Oct 14, 2026
Study completion
Jan 2028→Oct 2028
Oct 14, 2026
Enrollment
127→90
Oct 14, 2026
Eligibility
3 inclusion criteria edited; 3 exclusion criteria edited, 2 added
What changed in the criteria
Inclusion criteria
  • EditedPart A Single Ascending Dose (SAD) and B Multiple Ascending Dose (MADMD)
  • EditedHave a body mass index within the range of 18 to 34 kilogram/ per square meter (kg/m²) (inclusive).
  • EditedPart B (MADMD) Only
Exclusion criteria
  • EditedPart A (SAD) and B (MADMD)
  • EditedPart B (MADMD) Only
  • EditedHave an abnormal blood pressure or pulse rate, or both, as determined by the investigator, or have uncontrolled hypertension, defined as a systolic blood pressure greater than (>) 150 mm HgmmHg or a diastolic blood pressure >95 mm HgmmHg at Screening or Treatment Visits.
  • AddedDiagnostic assessments
  • AddedHemoglobin A1c 6.5 percent (%) or higher
Oct 14, 2026
Show all 1 update
  1. Oct 14, 2026
    Primary completion Jan 2028→Oct 2028
    Study completion Jan 2028→Oct 2028
    Enrollment 127→90
    Eligibility 3 inclusion criteria edited; 3 exclusion criteria edited, 2 added
    What changed in the criteria
    Inclusion criteria
    • EditedPart A Single Ascending Dose (SAD) and B Multiple Ascending Dose (MADMD)
    • EditedHave a body mass index within the range of 18 to 34 kilogram/ per square meter (kg/m²) (inclusive).
    • EditedPart B (MADMD) Only
    Exclusion criteria
    • EditedPart A (SAD) and B (MADMD)
    • EditedPart B (MADMD) Only
    • EditedHave an abnormal blood pressure or pulse rate, or both, as determined by the investigator, or have uncontrolled hypertension, defined as a systolic blood pressure greater than (>) 150 mm HgmmHg or a diastolic blood pressure >95 mm HgmmHg at Screening or Treatment Visits.
    • AddedDiagnostic assessments
    • AddedHemoglobin A1c 6.5 percent (%) or higher
    + 4 other changes: identifiers, verification date, description and arm descriptions

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06809400
Responsible party
Sponsor
First posted
Feb 5, 2025
Start date
Feb 18, 2025
Primary completion
Oct 2028 (estimated)
Completion
Oct 2028 (estimated)
Last update
Oct 14, 2026

Study contacts

Trial questions or participation questions: 1-877-CTLILLY (1-877-285-4559) or
Contact
LillyTrials@Lilly.com
1-317-615-4559
Physicians interested in becoming principal investigators please contact
Contact
clinical_inquiry_hub@lilly.com
Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 8 AM - 8 PM Eastern time (UTC/GMT - 5 hours, EST)
study director · Eli Lilly and Company

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion